Natixis Purchases 2,594 Shares of SPDR S&P Biotech ETF (NYSEARCA:XBI)

Natixis raised its stake in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) by 5.5% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 49,498 shares of the exchange traded fund’s stock after acquiring an additional 2,594 shares during the period. Natixis owned approximately 0.09% of SPDR S&P Biotech ETF worth $4,712,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Valeo Financial Advisors LLC grew its holdings in shares of SPDR S&P Biotech ETF by 165.2% in the second quarter. Valeo Financial Advisors LLC now owns 1,525 shares of the exchange traded fund’s stock valued at $144,000 after purchasing an additional 950 shares in the last quarter. Pacific Sun Financial Corp acquired a new position in shares of SPDR S&P Biotech ETF in the second quarter valued at approximately $201,000. First Republic Investment Management Inc. grew its holdings in shares of SPDR S&P Biotech ETF by 17.2% in the second quarter. First Republic Investment Management Inc. now owns 515,072 shares of the exchange traded fund’s stock valued at $49,030,000 after purchasing an additional 75,665 shares in the last quarter. BB&T Securities LLC grew its holdings in shares of SPDR S&P Biotech ETF by 5.8% in the second quarter. BB&T Securities LLC now owns 11,533 shares of the exchange traded fund’s stock valued at $1,097,000 after purchasing an additional 635 shares in the last quarter. Finally, Global Retirement Partners LLC grew its holdings in shares of SPDR S&P Biotech ETF by 29.8% in the second quarter. Global Retirement Partners LLC now owns 8,917 shares of the exchange traded fund’s stock valued at $849,000 after purchasing an additional 2,049 shares in the last quarter.

Shares of XBI stock opened at $89.50 on Tuesday. SPDR S&P Biotech ETF has a fifty-two week low of $78.46 and a fifty-two week high of $101.55.

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 26th. Investors of record on Monday, September 24th were issued a $0.0726 dividend. The ex-dividend date of this dividend was Friday, September 21st. This represents a $0.29 dividend on an annualized basis and a dividend yield of 0.32%. This is a boost from SPDR S&P Biotech ETF’s previous quarterly dividend of $0.06.

SPDR S&P Biotech ETF Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Featured Story: How to Track your Portfolio in Google Finance

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply